研究者業績

塚本 徹哉

ツカモト テツヤ  (Tetsuya Tsukamoto)

基本情報

所属
藤田医科大学 医学部病理診断学 教授
学位
医学博士(三重大学)

ORCID ID
 https://orcid.org/0000-0002-7502-8724
J-GLOBAL ID
200901034217428831
researchmap会員ID
5000002816

Tetsuya TSUKAMOTO is a full time Professor in the Department of Diagnostic Pathology, Fujita Health University School of Medicine, Toyoake, Japan. Medical Doctor (1987) in Mie University School of Medicine, Tsu, Japan and Doctor of Philosophy (1991) in Mie University Graduate School of Medicine, Tsu, Japan. Worked in cancer research in Aichi Cancer Center Research Institute, Nagoya, Japan, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, and University of California at Berkeley, Berkeley, CA, USA. Involved in Pathological field in Division of Oncological Pathology, Aichi Cancer Center Research Institute, Nagoya and Department of Diagnostic Pathology, Fujita Health University School of Medicine, Toyoake, Japan, steering the clinical, teaching, training and research works. Member of Digital Pathology Association, Japan, Japanese Society of Pathology, Japanese Society of Clinical Cytology, Japanese Society of Toxicologic Pathology, and Japanese Cancer Association. He has over 200 peer reviewed research publications in oncological and experimental pathology and more than 20 book chapters to his credit. Currently he is involved in image analysis using deep learning and computer-aided detection/diagnosis in pathological cytological fields.

学歴

 2

論文

 196
  • Alessandra Capuano, Maddalena Vescovo, Simone Canesi, Eliana Pivetta, Roberto Doliana, Maria Grazia Nadin, Masami Yamamoto, Tetsuya Tsukamoto, Sachiyo Nomura, Emanuela Pilozzi, Antonio Palumbo, Vincenzo Canzonieri, Renato Cannizzaro, Eugenio Scanziani, Gustavo Baldassarre, Maurizio Mongiat, Paola Spessotto
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 27(5) 1016-1030 2024年9月  
    BACKGROUND: The contribution of the tumor microenvironment and extracellular matrix to the aggressive biology of Gastric Cancer (GC) has been recently characterized; however, the role of EMILIN-1 in this context is unknown. EMILIN-1 is an essential structural element for the maintenance of lymphatic vessel (LV) integrity and displays anti-proliferative properties as demonstrated in skin and colon cancer. Given the key role of LVs in GC progression, the aim of this study was to investigate the role of EMILIN-1 in GC mouse models. METHODS: We used the syngeneic YTN16 cells which were injected subcutaneously and intraperitoneally in genetically modified EMILIN-1 mice. In alternative, carcinogenesis was induced using N-Methyl-N-nitrosourea (MNU). Mouse-derived samples and human biopsies were analyzed by IHC and IF to the possible correlation between EMILIN-1 expression and LV pattern. RESULTS: Transgenic mice developed tumors earlier compared to WT animals. 20 days post-injection tumors developed in EMILIN-1 mutant mice were larger and displayed a significant increase of lymphangiogenesis. Treatment of transgenic mice with MNU associated with an increased number of tumors, exacerbated aggressive lesions and higher levels of LV abnormalities. A significant correlation between the levels of EMILIN-1 and podoplanin was detected also in human samples, confirming the results obtained with the pre-clinical models. CONCLUSIONS: This study demonstrates for the first time that loss of EMILIN-1 in GC leads to lymphatic dysfunction and proliferative advantages that sustain tumorigenesis, and assess the use of our animal model as a valuable tool to verify the fate of GC upon loss of EMILIN-1.
  • Rie Kawasaki, Iwao Kukimoto, Tetsuya Tsukamoto, Eiji Nishio, Aya Iwata, Takuma Fujii
    Cancer Science 2024年8月22日  
    Abstract Approximately 660,000 women are diagnosed with cervical cancer annually. Current screening options such as cytology or human papillomavirus testing have limitations, creating a need to identify more effective ancillary biomarkers for triage. Here, we evaluated whether metabolomic analysis of cervical mucus metabolism could be used to identify biomarkers of cervical intraepithelial neoplasia (CIN) and cervical cancer. The case–control group consisted of 181 CIN, 69 squamous cell carcinoma (SCC) patients, and 48 healthy controls in the primary cohort. We undertook metabolomic analyses using ultra‐HPLC–tandem mass spectrometry. Univariate and multivariate analyses were carried out to profile metabolite characteristics, and receiver operating characteristic (ROC) analysis identified biomarker candidates. Five metabolites conferred the highest discriminatory power for SCC: oxidized glutathione (GSSG) (area under the ROC curve, 0.924; 95% confidence interval, 0.877–0.971), malic acid (0.914, 0.859–0.968), kynurenine (0.884, 0.823–0.945), GSSG/glutathione (GSH) (0.936, 0.892–0.979), and kynurenine/tryptophan (0.909, 0.856–0.961). Malic acid was the best marker for detection of CIN2 or worse (0.858, 0.793–0.922) and was a clinically useful metabolite. We confirmed the reproducibility of the results by validation cohort. Additionally, metabolomic analyses revealed eight pathways strongly associated with cervical neoplasia. Of these, only the tricarboxylic acid cycle was strongly associated with all CINs and cancer, indicating active energy production. Aberrant arginine metabolism by decreasing arginine and increasing citrulline might reduce tumor immunity. Changes in cysteine‐methionine and GSH pathways might drive the initiation and progression of cervical cancer. These results suggest that metabolic analysis can identify ancillary biomarkers and could improve our understanding of the pathophysiological mechanisms underlying cervical neoplasia.
  • Yu Jiang, Yawen Wang, Guofeng Chen, Fei Sun, Qijing Wu, Qiong Huang, Dongqiang Zeng, Wenjun Qiu, Jiao Wang, Zhiqi Yao, Bishan Liang, Shaowei Li, Jianhua Wu, Na Huang, Yuanyuan Wang, Jingsong Chen, Xiaohui Zhai, Li Huang, Beibei Xu, Masami Yamamoto, Tetsuya Tsukamoto, Sachiyo Nomura, Wangjun Liao, Min Shi
    Cell Metabolism 36(8) 1806-1822.e11 2024年8月  
  • Takayuki Owaki, Tadashi Iida, Yuki Miyai, Katsuhiro Kato, Tetsunari Hase, Makoto Ishii, Ryota Ando, Kunihiko Hinohara, Tomohiro Akashi, Yasuyuki Mizutani, Takuya Ishikawa, Shinji Mii, Yukihiro Shiraki, Nobutoshi Esaki, Masami Yamamoto, Tetsuya Tsukamoto, Sachiyo Nomura, Takashi Murakami, Masahide Takahashi, Yuri Yuguchi, Motohiro Maeda, Tomoyasu Sano, Naoto Sassa, Yoshihisa Matsukawa, Hiroki Kawashima, Shusuke Akamatsu, Atsushi Enomoto
    British journal of cancer 2024年6月7日  査読有り
    BACKGROUND: The proliferation of cancer-associated fibroblasts (CAFs) hampers drug delivery and anti-tumor immunity, inducing tumor resistance to immune checkpoint blockade (ICB) therapy. However, it has remained a challenge to develop therapeutics that specifically target or modulate CAFs. METHODS: We investigated the involvement of Meflin+ cancer-restraining CAFs (rCAFs) in ICB efficacy in patients with clear cell renal cell carcinoma (ccRCC) and urothelial carcinoma (UC). We examined the effects of Am80 (a synthetic retinoid) administration on CAF phenotype, the tumor immune microenvironment, and ICB efficacy in cancer mouse models. RESULTS: High infiltration of Meflin+ CAFs correlated with ICB efficacy in patients with ccRCC and UC. Meflin+ CAF induction by Am80 administration improved ICB efficacy in the mouse models of cancer. Am80 exerted this effect when administered prior to, but not concomitant with, ICB therapy in wild-type but not Meflin-deficient mice. Am80-mediated induction of Meflin+ CAFs was associated with increases in antibody delivery and M1-like tumor-associated macrophage (TAM) infiltration. Finally, we showed the role of Chemerin produced from CAFs after Am80 administration in the induction of M1-like TAMs. CONCLUSION: Our data suggested that Am80 administration prior to ICB therapy increases the number of Meflin+ rCAFs and ICB efficacy by inducing changes in TAM phenotype.
  • Takuma Fujii, Eiji Nishio, Tetsuya Tsukamoto, Iwao Kukimoto, Aya Iwata
    Cancer Science 2024年5月15日  
    Abstract Currently, human papillomavirus tests and cytology are used to screen for cervical cancer. However, more accurate ancillary screening tests are needed. MicroRNAs (miRNAs) and cytokines are promising biomarkers that are aberrantly expressed in cervical cancer. Therefore, the potential of developing new screening markers based on the levels of miRNAs and cytokines in serum and local mucus samples from the same patients with cervical neoplasia was investigated. miRNA screening was performed by microarray and measurement using real‐time reverse‐transcriptase PCR. Cytokine were measured using multiplex bead assay, and changes in expressions were analyzed based on disease severity. As lesions progressed, miR‐20b‐5p, −155‐5p, −144‐3p, −451a, and −126‐3p expression levels were increased in mucus, and miR‐16‐5p, −223‐3p, and ‐451a expression levels were decreased in serum. Regarding cytokines, IL‐6, IL‐8, monocyte chemoattractant protein‐1, Eotaxin, interferon‐γ, and RANTES were increased, whereas granulocyte–colony‐stimulating factor (G‐CSF) was significantly decreased in mucus. miRNAs and cytokines in serum did not have high diagnostic accuracy. However, a combination of miR‐20b‐5p, ‐451a, ‐126‐3p, Eotaxin, as well as G‐CSF in mucus samples, had high diagnostic accuracy with an area under the receiver operating characteristic curve of 0.989 (0.979–0.999). Our results suggest that using mucus for this ancillary test is more beneficial than serum.

MISC

 303
  • 中川 満, 浦野 誠, 櫻井 映子, 岡部 麻子, 熊澤 文久, 桐山 諭和, 塚本 徹哉, 溝口 良順, 黒田 誠
    日本小児血液・がん学会雑誌 52(1) 98-98 2015年3月  
  • 塚本 徹哉, 桐山 諭和
    日本胃癌学会総会記事 87回 275-275 2015年3月  
  • 桐山 諭和, 浦野 誠, 櫻井 映子, 中川 満, 岡部 麻子, 熊澤 文久, 塚本 徹哉, 溝口 良順, 黒田 誠
    日本病理学会会誌 104(1) 398-398 2015年3月  
  • 櫻井 映子, 中川 満, 岡部 麻子, 熊澤 文久, 桐山 諭和, 塚本 徹哉, 浦野 誠, 溝口 良順, 黒田 誠
    日本病理学会会誌 104(1) 428-428 2015年3月  
  • 塚本 徹哉, 桐山 諭和
    日本病理学会会誌 104(1) 475-475 2015年3月  
  • 中川 満, 浦野 誠, 櫻井 映子, 岡部 麻子, 熊澤 文久, 桐山 諭和, 塚本 徹哉, 溝口 良順, 黒田 誠
    日本病理学会会誌 104(1) 485-485 2015年3月  
  • 岡部 麻子, 安倍 雅人, 櫻井 映子, 中川 満, 熊澤 文久, 桐山 諭和, 塚本 徹哉, 浦野 誠, 溝口 良順, 黒田 誠
    日本病理学会会誌 104(1) 488-488 2015年3月  
  • 平田 暁大, 山田 泰広, 富田 弘之, 塚本 徹哉, 原 明
    日本毒性病理学会講演要旨集 31回 62-62 2015年1月  
  • 豊田 武士, 小川 久美子, 塚本 徹哉, 立松 正衞
    G.I.Research 22(6) 487-493 2014年12月  
    Helicobacter pylori(H.pylori)感染は、スナネズミの胃粘膜に腸上皮化生および胃型・腸型の異所性増殖性腺管を誘発するが、いずれも除菌後には消滅し胃癌は発生しない。H.pylori非感染動物(スナネズミ・マウス・ラット)に対して化学発がん物質で誘導した胃癌はすべて胃型であり、腸上皮化生の発生は伴わない。H.pylori感染スナネズミにおける化学発癌では胃型胃癌に加え、腸上皮化生と腸型胃癌が形成される。すなわち、胃粘膜の腸型化(腸上皮化生ならびに腸型胃癌)はH.pylori感染が主要因である。H.pyloriは胃発がんに対する強力なプロモーション作用を有し、除菌治療は胃癌抑制効果を示す。除菌後の胃粘膜はH.pyloriによる発がん促進作用を失い、新たな腸型化が起きない状況となる。スナネズミの除菌後胃癌には腸型の形質が混じることから、除菌後胃癌は新生胃癌ではなく、除菌前に存在していた潜在癌が顕在化したものと考えるのが妥当である。(著者抄録)
  • Xueyuan Cao, Dong Hui Cao, Jing Jiang, Tetsuya Tsukamoto, Masahiro Oshima
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 29 251-251 2014年11月  
  • Dong Hui Cao, Xueyuan Cao, Jing Jiang, Tetsuya Tsukamoto, Masahiro Oshima
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 29 252-252 2014年11月  
  • Harunobu Sato, Tetsuya Tsukamoto, Yoshihisa Mizuno, Tomoaki Ichikawa, Yoshihito Kotani, Katsuyuki Honda, Kouhei Hatta, Makoto Kuroda
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 26(6) 749-51 2014年11月  査読有り
    Malakoplakia in the gastrointestinal tract is rare in healthy young people without underlying disease. Sufficient tissue is required for accurate diagnosis. We describe a malakoplakia that developed in a healthy young woman and was treated by endoscopic mucosal resection (EMR). A 40-year-old woman with a history of taking oral contraceptives until one year earlier was referred to our hospital with anal bleeding and constipation. A colonoscopy carried out at our another hospital 18 months earlier disclosed no abnormal findings. Colonoscopy at presentation revealed a yellowish-white tumor, 5 mm in diameter, in the rectum. The lesion was slightly protruded and had a smooth flat surface, without erosion or ulceration. EMR was carried out for a definitive diagnosis. Histopathological examination showed that the tumor contained granular histiocytes, positive for CD68 and negative forcytokeratin (AE1/AE3). Several histiocytes contained intracytoplasmic round bodies (Michaelis-Gutmann bodies), which reacted positively with periodic acid-Schiff and calcium (Von Kossa) stains. Intracytoplasmic Escherichia coli (von Hansemann bodies) were identified by Giemsa staining. Based on these results, the tumor in the rectum was diagnosed as a malakoplakia. Following EMR, the patient did not receive further treatment for malakoplakia because she had no symptoms associated with malakoplakia. She has been well for more than 9 months, with no symptoms of disease. Awareness of colorectal malakoplakia is important in patients taking steroids, including oral contraceptives.
  • 平澤 浩, 伊藤 里美, 藤原 真紀, 川島 佳晃, 桐山 諭和, 塚本 徹哉, 浦野 誠, 溝口 良順, 黒田 誠
    日本臨床細胞学会雑誌 53(Suppl.2) 578-578 2014年10月  
  • 浦野 誠, 川島 佳晃, 藤原 真紀, 伊藤 里美, 平澤 浩, 桐山 諭和, 塚本 徹哉, 溝口 良順, 黒田 誠
    日本臨床細胞学会雑誌 53(Suppl.2) 597-597 2014年10月  
  • 櫻井 靖高, 横井 雅幸, 塚本 徹哉, 小田 司, 魏 民, 山下 孝之, 鰐渕 英機, 立松 正衛, 村雲 芳樹, 花岡 文雄
    日本癌学会総会記事 73回 P-3076 2014年9月  
  • 溝口 良順, 黒田 誠, 浦野 誠, 塚本 徹哉, 桐山 諭和, 熊澤 文久, 岡部 麻子, 中川 満, 櫻井 映子
    日本病理学会会誌 103(2) 66-66 2014年9月  
  • 桐山 諭和, 塚本 徹哉
    日本癌学会総会記事 73回 P-2338 2014年9月  
  • 桐山 諭和, 浦野 誠, 塚本 徹哉, 引地 克, 熊澤 文久, 岡部 麻子, 溝口 良順, 白木 良一, 都築 豊徳, 黒田 誠
    診断病理 31(3) 218-222 2014年7月  
    症例は60代男性。膀胱癌再発を疑って施行されたTUR-BT検体で、尿細管様構造を模倣する小型腺管が密に増殖しておりnephrogenic adenoma(NA)と診断した。術後定期的な経過観察がされていた5年後、再度同様の像を認めた。NAは生検診断時に尿路上皮癌や膀胱明細胞腺癌、浸潤性前立腺癌などとの鑑別が問題となることがあり病理診断医が知っておくべき良性病変の1つである。今回、膀胱尿路上皮癌の経過観察中に継続して認められた膀胱の多発NAの1例を経験したので報告する。(著者抄録)
  • Tetsuya Tsukamoto, Masae Tatematsu
    Current infectious disease reports 16(5) 402-402 2014年5月  査読有り
    Helicobacter pylori infection is one of the most important factors in gastric carcinogenesis in humans. Epidemiological studies have revealed that H. pylori-infected patients develop significantly more gastric cancers than uninfected individuals. In rodent models, H. pylori inoculation causes strong promoting effects in carcinogen-treated animals, whereas the bacterial infection alone causes only hyperplasic, atrophic, and/or metaplastic lesions. In both human and rodent models, eradication of H. pylori helps inhibit gastric carcinogenesis, especially when there is only mild gastric inflammation and no evidence of severe atrophy or intestinal metaplasia. Chemoprevention studies in humans have been reported and have shown the effectiveness of several medications including a cyclooxygenase-2 inhibitor. Candidate chemicals used in rodent models could hopefully be used in humans in the future.
  • E. Okochi-Takada, N. Hattori, T. Tsukamoto, K. Miyamoto, T. Ando, S. Ito, Y. Yamamura, M. Wakabayashi, Y. Nobeyama, T. Ushijima
    ONCOGENE 33(17) 2273-2278 2014年4月  査読有り
    Tumor suppressors with extracellular function are likely to have advantages as targets for cancer therapy, but few are known. Here, we focused on angiopoietin-like 4 (ANGPTL4), which is a secreted glycoprotein involved in lipoprotein metabolism and angiogenesis, is methylation-silenced in human cancers, but has unclear roles in cancer development and progression. We found a deletion mutation in its coiled-coil domain at its N-terminal in human gastric cancers, in addition to hypermethylation of the ANGPTL4 promoter CpG islands. Forced expression of wild-type ANGPTL4, but not ANGPTL4 with the deletion, at physiological levels markedly suppressed in vivo tumorigenicity and tumor angiogenesis, indicating that the latter caused the former. Tumor-derived ANGPTL4 suppressed in vitro vascular tube formation and proliferation of human umbilical vascular endothelial cells, partly due to suppression of ERK signaling. These showed that ANGPTL4 is a genetically and epigenetically inactivated secreted tumor suppressor that inhibits tumor angiogenesis.
  • 岡部 麻子, 中川 満, 櫻井 映子, 熊澤 文久, 桐山 諭和, 塚本 徹哉, 浦野 誠, 溝口 良順, 黒田 誠
    日本病理学会会誌 103(1) 312-312 2014年3月  
  • 塚本 徹哉, 豊田 武士, 山本 昌美, 桐山 諭和, 立松 正衞
    日本病理学会会誌 103(1) 330-330 2014年3月  
  • 中川 満, 桐山 諭和, 浦野 誠, 櫻井 映子, 岡部 麻子, 熊澤 文久, 塚本 徹哉, 溝口 良順, 黒田 誠
    日本病理学会会誌 103(1) 343-343 2014年3月  
  • Toyoda, T, Yamamoto, M, Takasu, S, Ogawa, K, Tatematsu, M, Tsukamoto, T
    Diseases 2 168-186 2014年  査読有り
  • Jun Fang, Takahiro Seki, Tetsuya Tsukamoto, Haibo Qin, Hongzhuan Yin, Long Liao, Hideaki Nakamura, Hiroshi Maeda
    Carcinogenesis 34(12) 2833-2841 2013年12月  査読有り
    Oxidative stress is associated with various pathological processes including inflammatory bowel disease, which is a major cause of colon cancer. Here, we examined the antioxidative and antiinflammatory effects of 4-vinyl-2,6-dimethoxyphenol (canolol), a potent antioxidant compound obtained from crude canola oil. Oral administration of 2% dextran sulfate sodium (DSS) resulted in the progression of colitis with shortening of the large bowel length. Administering a diet containing canolol significantly suppressed pathogenesis diarrhea markedly improved and the length of large bowel returned to almost normal. Pathological examination clearly revealed improvement of colonic ulcers. Production of inflammatory cytokines, i.e. interleukin-12 and tumor necrosis factor-α, was significantly increased during this pathological process their production was markedly inhibited by canolol. In the azoxymethane/DSS-induced colon cancer model, mice receiving canolol had a reduced occurrence of cancer, to 60%, compared with control mice, 100% of which had colon cancer. The numbers of tumors in each mouse were also significantly reduced in mice receiving the canolol-containing diet (5.6 ± 2.0) compared with azoxymethane/DSS control mice (10.8 ± 4.2). No apparent toxicity of canolol was observed. Moreover, inflammatory cytokines (i.e. cyclooxygenase-2, inducible nitric oxide synthase and tumor necrosis factor-α) and oxidative responding molecules, i.e. heme oxygenase-1, in colon were suppressed during this treatment. In a mouse colon 26 solid tumor model, canolol significantly suppressed cyclooxygenase-2 expression however, no significant tumor growth inhibition was observed, suggesting that canolol preferably shows chemopreventive effects during the stages of initiation/promotion. Canolol may, thus, be considered a potential cancer preventive agent or supplement. © The Author 2013. Published by Oxford University Press.
  • 平田 暁大, 山田 泰広, 富田 弘之, 塚本 徹哉, 山本 昌美, 二上 英樹, 原 明
    日本獣医学会学術集会講演要旨集 156回 397-397 2013年8月  
  • Takeshi Toyoda, Tetsuya Tsukamoto, Masami Yamamoto, Hisayo Ban, Noriko Saito, Shinji Takasu, Liang Shi, Ayumi Saito, Seiji Ito, Yoshitaka Yamamura, Akiyoshi Nishikawa, Kumiko Ogawa, Takuji Tanaka, Masae Tatematsu
    BMC GASTROENTEROLOGY 13 122 2013年7月  査読有り
    Background: Helicobacter pylori (H. pylori) infection and excessive salt intake are known as important risk factors for stomach cancer in humans. However, interactions of these two factors with gene expression profiles during gastric carcinogenesis remain unclear. In the present study, we investigated the global gene expression associated with stomach carcinogenesis and prognosis of human gastric cancer using a mouse model. Methods: To find candidate genes involved in stomach carcinogenesis, we firstly constructed a carcinogen-induced mouse gastric tumor model combined with H. pylori infection and high-salt diet. C57BL/6J mice were given N-methyl-N-nitrosourea in their drinking water and sacrificed after 40 weeks. Animals of a combination group were inoculated with H. pylori and fed a high-salt diet. Gene expression profiles in glandular stomach of the mice were investigated by oligonucleotide microarray. Second, we examined an availability of the candidate gene as prognostic factor for human patients. Immunohistochemical analysis of CD177, one of the up-regulated genes, was performed in human advanced gastric cancer specimens to evaluate the association with prognosis. Results: The multiplicity of gastric tumor in carcinogen-treated mice was significantly increased by combination of H. pylori infection and high-salt diet. In the microarray analysis, 35 and 31 more than two-fold up-regulated and down-regulated genes, respectively, were detected in the H. pylori-infection and high-salt diet combined group compared with the other groups. Quantitative RT-PCR confirmed significant over-expression of two candidate genes including Cd177 and Reg3g. On immunohistochemical analysis of CD177 in human advanced gastric cancer specimens, over-expression was evident in 33 (60.0%) of 55 cases, significantly correlating with a favorable prognosis (P = 0.0294). Multivariate analysis including clinicopathological factors as covariates revealed high expression of CD177 to be an independent prognostic factor for overall survival. Conclusions: These results suggest that our mouse model combined with H. pylori infection and high-salt diet is useful for gene expression profiling in gastric carcinogenesis, providing evidence that CD177 is a novel prognostic factor for stomach cancer. This is the first report showing a prognostic correlation between CD177 expression and solid tumor behavior.
  • Jing Jiang, Dong-Hui Cao, Tetsuya Tsukamoto, Guo-Qing Wang, Zhi-Fang Jia, Jian Suo, Xue-Yuan Cao
    ONCOLOGY LETTERS 5(5) 1562-1566 2013年5月  査読有り
    Gastric cancer remains the fourth most commonly diagnosed cancer and is the second leading cause of cancer-related mortality worldwide. The aim of this study was to investigate the effects of canolol on the proliferation and apoptosis of SGC-7901 human gastric cancer cells. and its relevant molecular mechanisms. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to observe the effect of canolol on the proliferation of SGC-7901 human gastric adenocarcinoma cells. The results showed that SGC-7901 cells exhibited a marked dose-dependent reduction in the proliferation rate. The survival rate of the cells was 88.86 +/- 1.58% at 50 mu mol/l, decreasing to 53.73 +/- 1.51% at 800 mu mol/l (P<0.05). By contrast, canolol had no significant toxicity on the human gastric mucosal epithelial cell line GES-1. The vivid images of cell morphology using an inverted microscope provided confirmation of the MTT assay. Treatment of SGC-7901 cells with canolol resulted in apoptosis demonstrated by flow cytometry. Furthermore, canolol downregulated the mRNA levels of COX-2, but had no significant effect on the mRNA expession of the Bax and Bcl-2 genes. These findings suggest that canolol has potential to be developed as a new natural anti-gastric carcinoma agent.
  • K. Asada, T. Ando, T. Niwa, S. Nanjo, N. Watanabe, E. Okochi-Takada, T. Yoshida, K. Miyamoto, S. Enomoto, M. Ichinose, T. Tsukamoto, S. Ito, M. Tatematsu, T. Sugiyama, T. Ushijima
    ONCOGENE 32(17) 2140-2149 2013年4月  査読有り
    Tumor-suppressor genes on chromosome X can be inactivated by a single hit, any of the point mutations, chromosomal loss and aberrant DNA methylation. As aberrant DNA methylation can be induced frequently, we here aimed to identify a tumor-suppressor gene on chromosome X inactivated by promoter DNA methylation. Of 69 genes on chromosome X upregulated by treatment of a gastric cancer cell line with a DNA-demethylating agent, 5-aza-2'-deoxycytidine, 11 genes had low or no expression in the cell line and abundant expression in normal gastric mucosae. Among them, FHL1 was frequently methylation-silenced in gastric and colon cancer cell lines, and methylated in primary gastric (21/80) and colon (5/50) cancers. Knockdown of the endogenous FHL1 in two cell lines by two kinds of shRNAs significantly increased cell growth in vitro and sizes of xenografts in nude mice. Expression of exogenous FHL1 in a non-expressing cell line significantly reduced its migration, invasion and growth. Notably, a somatic mutation (G642T; Lys214Asn) was identified in one of 144 colon cancer specimens, and the mutant FHL1 was shown to lack its inhibitory effects on migration, invasion and growth. FHL1 methylation was associated with Helicobacter pylori infection and accumulated in normal-appearing gastric mucosae of gastric cancer patients. These data showed that FHL1 is a methylation-silenced tumor-suppressor gene on chromosome X in gastrointestinal cancers, and that its silencing contributes to the formation of an epigenetic field for cancerization. Oncogene (2013) 32, 2140-2149; doi:10.1038/onc.2012.228; published online 11 June 2012
  • Tohru Niwa, Takeshi Toyoda, Tetsuya Tsukamoto, Akiko Mori, Masae Tatematsu, Toshikazu Ushijima
    CANCER PREVENTION RESEARCH 6(4) 263-270 2013年4月  査読有り
    Suppression of aberrant DNA methylation is a novel approach to cancer prevention, but, so far, the efficacy of the strategy has not been evaluated in cancers associated with chronic inflammation. Gastric cancers induced by Helicobacter pylori infection are known to involve aberrant DNA methylation and associated with severe chronic inflammation in their early stages. Here, we aimed to clarify whether suppression of aberrant DNA methylation can prevent H. pylori-induced gastric cancers using a Mongolian gerbil model. Administration of a DNA demethylating agent, 5-aza-2'-deoxycytidine (5-aza-dC), to gerbils (0.125 mg/kg for 50-55 weeks) decreased the incidence of gastric cancers induced by H. pylori infection and N-methyl-N-nitrosourea (MNU) treatment from 55.2% to 23.3% (P < 0.05). In gastric epithelial cells, DNA methylation levels of six CpG islands (HE6, HG2, SB1, SB5, SF12, and SH6) decreased to 46% to 68% (P < 0.05) of gerbils without 5-aza-dC treatment. Also, the global DNA methylation level decreased from 83.0% +/- 4.5% to 80.3% +/- 4.4% (mean +/- SD) by 5-aza-dC treatment (P < 0.05). By 5-aza-dC treatment, Il1b and Nos2 were downregulated (42% and 58% of gerbils without, respectively) but Tnf was upregulated (187%), suggesting that 5-aza-dC treatment induced dysregulation of inflammatory responses. No obvious adverse effect of 5-aza-dC treatment was observed, besides testicular atrophy. These results showed that 5-aza-dC treatment can prevent H. pylori-induced gastric cancers and suggested that removal of induced DNA methylation and/or suppression of DNA methylation induction can become a target for prevention of chronic inflammation-associated cancers. Cancer Prev Res; 6(4); 263-70. (c) 2013 AACR.
  • Tetsuya Tsukamoto, Takeshi Toyoda, Tsutomu Mizoshita, Masae Tatematsu
    Seminars in immunopathology 35(2) 177-90 2013年3月  査読有り
    Helicobacter pylori infection is an important factor for gastric carcinogenesis in human. In carcinogen-treated Mongolian gerbils, H. pylori infection enhances stomach carcinogenesis, while infection alone induced severe hyperplasia called heterotopic proliferative glands. A high-salt diet or early acquisition of the bacteria exacerbates inflammation and carcinogenesis. Oxygen radical scavengers or anti-inflammatory chemicals as well as eradication of H. pylori are effective to prevent carcinogenesis. H. pylori-associated inflammation induces intestinal metaplasia and intestinalization of stomach cancers independently. It is necessary to control cancer development not only in H. pylori-positive cases but also in H. pylori-negative metaplastic gastritis.
  • 塚本徹哉
    臨床消化器内科 28 131-136 2013年  
  • 塚本徹哉
    臨床消化器内科 28 502-508 2013年  
  • Ayumi Nojiri, Takeshi Toyoda, Takuji Tanaka, Toshimichi Yoshida, Masae Tatematsu, Tetsuya Tsukamoto
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION 14(7) 4135-4139 2013年  査読有り
    Inflammation is potential risk factor of various human malignancies. Inflammatory bowel syndromes such as ulcerative colitis are well known as risk factors for colon cancer. Here, we examined enhancing effects of dextran sulfate sodium (DSS)-associated inflammation on X-irradiation induced colonic tumorigenesis in Min and wild-type (WT) mice. Animals were X-irradiated at 1.5 Gy at 5 weeks of age (at 0 experimental week) and 2% DSS in drinking water was administered at 5 or 11 experimental weeks. Mice were sacrificed at 16 weeks and incidence and multiplicity of colonic tumors were assessed. Incidence of colonic tumors in Min mouse was increased from 33.3% to 100% (p<0.05) with X-irradiation alone, whereas no tumors were developed in WT mice. In DSS-treated Min mice, X-irradiation increased the number of colonic tumors. Total number of colonic tumors was increased 1.57 times to 30.7 +/- 3.83 tumors/mouse with X-irradiation+DSS at 5 weeks comapared to 19.6 +/- 2.9 in corresponding DSS alone group (p<0.05). When the duration of inflammation was compared, longer period of DSS effect promoted more colonic tumorigenesis. Collectively, we conclude that X-irradiation and DSS-induced inflammation act synergistically for colonic tumorigenesis.
  • Xueyuan Cao, Jing Jiang, Hong-Xi Ma, Donghui Cao, Mei-Shan Jin, Tetsuya Tsukamoto
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 165-165 2012年12月  
  • Xueyuan Cao, Jing Jiang, Donghui Cao, Tetsuya Tsukamoto, Hiroshi Maeda
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 334-335 2012年12月  
  • Xueyuan Cao, Jing Jiang, Ru-Ming Liu, Lin Ma, Donghui Cao, Tetsuya Tsukamoto, Hiroshi Maeda, Masanobu Oshima
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 413-413 2012年12月  
  • 豊田 武士, 塚本 徹哉, 高須 伸二, 時 亮, 立松 正衛, 曹 永晩, 大波 冴子, 西川 秋佳, 小川 久美子
    日本癌学会総会記事 71回 105-105 2012年8月  
  • Yasuyuki Shigematsu, Tohru Niwa, Satoshi Yamashita, Hirokazu Taniguchi, Ryoji Kushima, Hitoshi Katai, Seiji Ito, Tetsuya Tsukamoto, Masao Ichinose, Toshikazu Ushijima
    ONCOLOGY LETTERS 4(2) 268-274 2012年8月  査読有り
    The accurate detection of the presence of lymph node metastases (LNM) of gastric cancers (GCs) is useful for the implementation of necessary and sufficient treatment, but current methods of detection are unsatisfactory. In the present study, we focused on DNA methylation markers since they have several advantages, including biological and chemical stability and informativeness even in the presence of contaminating cells. Using three metastatic lymph nodes and three primary GCs without LNM, methylation bead array analyses were performed, which enabled the interrogation of 485,577 CpG sites. A total of 31 CpG sites that were hypermethylated in the metastatic lymph nodes, compared with the GCs without LNM, were isolated. Using primary GCs with and without LNM (28 GCs with LNM and 10 without), their methylation levels were measured using quantitative PCR following treatment with sodium bisulfite or a methylation-sensitive restriction enzyme. Of the genomic regions around the 31 CpG sites, 10 regions demonstrated higher methylation levels in the GCs with LNM compared with the GCs without LNM (P<0.05). Finally, the hypermethylation of the 10 regions was validated using another set of samples (129 GCs with LNM and 20 without). Hypermethylation of the region around the cg06436185 CpG site predicted the presence of LNM at a sensitivity of 43% and specificity of 85%. Additionally, the hypermethylation of the region was associated with a poor survival rate among GC patients with LNM. The results of the present study indicated that the methylation status of the region was a promising candidate marker to detect the presence of LNM of GCs and may reflect the malignant potential of GCs.
  • 豊田武士, 塚本徹哉, 高須伸二, 時亮, 齋藤亜弓, 齋藤典子, 立松正衞, CHO Young‐Man, 西川秋佳, 小川久美子
    日本毒性病理学会講演要旨集 28th 107-107 2012年2月  
  • 豊田武士, 塚本徹哉, 高須伸二, 時亮, 田中卓二, 立松正衞, 西川秋佳, 小川久美子
    日本がん予防学会プログラム・抄録集 19th 45 2012年  

書籍等出版物

 7

講演・口頭発表等

 76

共同研究・競争的資金等の研究課題

 20

教育内容・方法の工夫(授業評価等を含む)

 1
  • 件名
    組織診断評価方法の説明
    開始年月日
    2011/04
    終了年月日
    2013/03
    概要
    臨床実習に陽性対照を示して、適確な組織診断をする方法を説明した。

作成した教科書、教材、参考書

 1
  • 件名
    毒性病理組織学改訂版
    概要
    「腺胃glandular stomach」を分担執筆

その他教育活動上特記すべき事項

 3
  • 件名
    第27回藤田保健衛生大学医学部医学教育ワークショップ
    開始年月日
    2009/04/11
    終了年月日
    2009/04/12
    概要
    「小グループ学習の充実」
  • 件名
    三重大学全学FD
    終了年月日
    2010/09/14
    概要
    「多様なPBLを導入した授業デザイン」
  • 件名
    第1回藤田保健衛生大学大学院ファカルティデベロップメント(FD)講習会
    終了年月日
    2012/07/25
    概要
    「 バーチャルスライドシステムの教育・研修への利用:サーバ運用における個人情報保護の留意点」を受講